A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Daxdilimab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms RECAST SLE
- Sponsors Amgen; Viela Bio
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 21 Jul 2023 Primary endpoint (Proportion of Participants who achieve BICLA and OGC (oral glucocorticoid) reduction response at Week 48) has not been met as per Horizon Therapeutics plc Media Release
- 21 Jul 2023 Results published in the Horizon Therapeutics plc Media Release